Emergent BioSolutions Inc.
Emergent BioSolutions Inc. (EBS): 19 pipeline candidates · 9 upcoming catalysts · ~27 mo cash runway · 14 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
27.0 months
D/E 1.52 · 9% dilution
Lead: Approved
19 candidates
9 upcoming, next in ~1906d
0 buys · 8 sells (180d)
A transparent, data-derived signal for Emergent BioSolutions Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$429.3M
Cash
$161.5M
Quarterly Burn
$33.8M
Runway
27.0 mo
Revenue
$156.1M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (19 candidates)
| Drug | Phase |
|---|---|
| acam2000 | Approved |
| aigiv | — |
| anthrasil | Approved |
| av7909 | Phase 2 |
| bat | Approved |
| biothrax | Phase 2 |
| blood sample collection | Phase 4 |
| cnj-016 | Approved |
| collection of samples | Phase 4 |
| covid-hig | Phase 1 |
Showing 10 of 19 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Loss of exclusivity — patent/exclusivity expiry opens the door to generic or biosimilar competition that can erode revenue.
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
190
Total value held
$358.4M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 4,515,990 | $37.5M |
| blackrock, inc. | 4,341,462 | $36.0M |
| state street corp | 2,849,701 | $23.7M |
| dimensional fund advisors lp | 2,757,158 | $22.9M |
| american century companies inc | 2,425,722 | $20.1M |
| charles schwab investment management inc | 1,506,075 | $12.5M |
| geode capital management, llc | 1,272,909 | $10.6M |
| palisade capital management, lp | 1,201,323 | $10.0M |
| vanguard portfolio management llc | 1,117,278 | $9.3M |
| oak hill advisors lp | 1,113,338 | $9.2M |
Showing top 10 of 190 institutional holders of Emergent BioSolutions Inc.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in Emergent BioSolutions Inc.'s pipeline?
Emergent BioSolutions Inc. (EBS) has 19 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Emergent BioSolutions Inc.'s lead drug candidate?
Emergent BioSolutions Inc.'s most advanced tracked candidate is acam2000 (Approved) for Active immunization for the prevention of smallpox and mpox disease.
What is Emergent BioSolutions Inc.'s next catalyst?
Emergent BioSolutions Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent/Exclusivity Expiry: LYNAVOY" — expected September 6, 2031.
What is Emergent BioSolutions Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Emergent BioSolutions Inc. has approximately 27.0 months of cash runway.
What is Emergent BioSolutions Inc.'s market capitalization?
Emergent BioSolutions Inc.'s market capitalization is approximately $429.3M.
Get the full picture on Emergent BioSolutions Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.